- Regorafenib for patients with previously untreated metastatic or unresectable renal-cell carcinoma: a single-group phase 2 trialTim Eisen
Cambridge University Health Partners, Cambridge, UK
Lancet Oncol 13:1055-62. 2012..This phase 2, open-label, non-randomised study assessed the safety and efficacy of the multikinase inhibitor regorafenib for treatment of renal-cell carcinoma...
- Fatal case of sorafenib-associated idiosyncratic hepatotoxicity in the adjuvant treatment of a patient with renal cell carcinomaB P Fairfax
Department of Oncology, Cancer and Haematology Centre, Churchill Hospital, Oxford OX3 7LJ, UK
BMC Cancer 12:590. 2012..The SORCE trial is designed to investigate whether treatment with adjuvant sorafenib can reduce recurrence rates in this cohort...